Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
|Videos|March 1, 2022
Improvements in bone-metastasis-related pain and QoL demonstrated in mCRPC with Lutetium-177 PSMA-617
Author(s)Urology Times staff
Advertisement
In this video, Brian D. Gonzalez, PhD, discusses the background, findings, and takeaways of the study, “Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gonzalez is an associate member and quality of life researcher at Moffitt Cancer Center in Tampa, Florida.
Advertisement
Related to this article
The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5